CLPT 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-03

• In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in

• benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery.

• Our neurosurgery navigation and therapy revenue primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRAflow systems. Generating recurring revenue from the sale of disposable products is an important part of our business model. Future revenue from …

• Our biologics and drug delivery revenue comes from sales of products, including disposable products, and services related to customer-sponsored preclinical and clinical trials utilizing our products. Our biologics and drug delivery customers are pharmaceutical and biotech companies, academic institu…

• Our capital equipment and software revenue consists of sales of ClearPoint and IRRAflow reusable hardware and software and related services.

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• In 2021, we started providing consulting services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in benchtop testing, preclinical studies, clinical trial support, regul…

• Generating recurring revenue from the sale of products is an important part of our business model for our ClearPoint system. Future revenue from sales of our ClearPoint platform products and services is difficult to predict and may not be sufficient to offset our continuing research and development …

• As a result of the IRRAS acquisition, revenue is expected to grow over the coming years due to a larger combined organization, expanded product offerings, and increased customer reach, both in the U.S. and internationally.

• Substantially all our revenue for the three months ended March 31, 2026 and 2025 relates to: (i) sales of our ClearPoint and IRRAflow system products and related services; and (ii) consulting services from our customers in the biologics and drug delivery space. Our product revenue was $8.8 million f…

• Our revenue from sales of products and services to our biologics and drug delivery customers comes from pharmaceutical and biotech companies, academic institutions, or customer-sponsored contract research organizations that are developing methods to deliver a wide variety of molecules, genes or prot…

相对上期新增的文字 · 来源:10-Q · 2026-08-03

• An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2025 10-K, in addition to other information in this report, before investing in our common stock. The occurrence of any of these risks could have a m…

• Establishing and operating our preclinical CRO facility (CAL) is capital intensive and subject to significant execution risk, and we may not realize the anticipated benefits of this investment.

• We are investing significant capital and management resources to build out, equip, and operate our preclinical contract research organization facility (CAL) to provide preclinical services, including Good Laboratory Practice (GLP) study services, to biopharmaceutical customers. Standing up and scali…

• The build-out and commissioning of the facility are subject to risks that could delay or increase the cost of making it operational, including construction and permitting delays, cost overruns, supply chain constraints or delays in the delivery, installation, and qualification of capital equipment, …

• Our ability to perform certain services, including GLP-compliant studies, depends on achieving and maintaining the appropriate regulatory and quality standards for the facility and its processes. We may be unable to establish, validate, or maintain GLP compliance or other required standards on the t…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• An investment in shares of our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in our 2025 10-K, in addition to other information in this report, before investing in our common

• stock. The occurrence of any of these risks could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. There have b…

相对上期新增的文字 · 来源:10-Q · 2026-08-03

• On June 4, 2026, Lynnette C. Fallon, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan's maximum duration is until December 31, 2027. The maximum number of shares to be sold under the p…

• On June 10, 2026, Matthew Klein, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan's maximum duration is until July 31, 2027. The maximum number of shares to be sold under the plan is 5…